Patents by Inventor Le Hoa Mai

Le Hoa Mai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies directed against the alpha chain of IL7 receptor—their use for the preparation of drug candidates
    Patent number: 9447182
    Abstract: The invention concerns antibodies directed against CD127, I.e. the alpha chain of the receptor for interleukin7 (IL-7), especially the receptor for human IL-7 expressed on human cells (designated human IL-7R alpha or IL-7Ra) or the TSLP receptor. The antibodies of the invention have cytotoxic activity against CD127 positive cells. The invention also relates to the use of these antibodies in order to deplete subpopulations of T lymphocytes as a result of cytotoxic action of the antibodies, through ADCC and optionally through CDC. Accordingly the invention concerns the use of the antibodies in the treatment of transplant rejection, autoimmune diseases, allergic diseases, lymphoma or cancer when these pathologies are associated with CD127 positive cells.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: September 20, 2016
    Assignees: OSE IMMUNOTHERAPEUTICS, INSTITUT NATIONAL DE LA SANTE ET LA RECHERCHE MEDICALE
    Inventors: Sophie Brouard, Le Hoa Mai, Caroline Mary, Nicolas Poirier, Jean-Paul Soulillou, Bernard Vanhove
  • ANTIBODIES DIRECTED AGAINST THE ALPHA CHAIN OF IL7 RECEPTOR - THEIR USE FOR THE PREPARATION OF DRUG CANDIDATES
    Publication number: 20140308281
    Abstract: The invention concerns antibodies directed against CD127, I.e. the alpha chain of the receptor for interleukin7 (IL-7), especially the receptor for human IL-7 expressed on human cells (designated human IL-7R alpha or IL-7Ra) or the TSLP receptor. The antibodies of the invention have cytotoxic activity against CD127 positive cells. The invention also relates to the use of these antibodies in order to deplete subpopulations of T lymphocytes as a result of cytotoxic action of the antibodies, through ADCC and optionally through CDC. Accordingly the invention concerns the use of the antibodies in the treatment of transplant rejection, autoimmune diseases, allergic diseases, lymphoma or cancer when these pathologies are associated with CD127 positive cells.
    Type: Application
    Filed: October 4, 2012
    Publication date: October 16, 2014
    Inventors: Sophie Brouard, Le Hoa Mai, Caroline Mary, Nicolas Poirier, Jean-Paul Soulillou, Bernard Vanhove